Antiproliferative activity of the Au–peptide conjugates, free peptides modified with a propargylglycine group (L1–L4), AuDPPBX, auranofin, cisplatin, and RAPTA-C against human ovarian carcinoma (A2780), human ovarian carcinoma cisplatin-resistant (A2780cisR) and human embryonic kidney 293 (HEK293) cell lines after 72 h exposurea.
| Compound | A2780 | A2780cisR | HEK293 |
|---|---|---|---|
| Au–LANA | 35 ± 3 | 42 ± 3 | >100 |
| LANA–Au | 36 ± 3 | 46 ± 3 | >100 |
| Au–GAG | 40 ± 4 | 36 ± 2 | >100 |
| GAG–Au | 53 ± 6 | 50 ± 5 | >100 |
| L1 | >200 | >200 | >200 |
| L2 | >200 | >200 | >200 |
| L3 | >200 | >200 | >200 |
| L4 | >200 | >200 | >200 |
| AuDPPBX | 6.9 ± 0.8 | 12.0 ± 2 | 11.7 ± 0.4 |
| Auranofin | 1.1 ± 0.1 | 2.6 ± 0.3 | 1.7 ± 0.8 |
| Cisplatin | 1.6 ± 0.9 | 17 ± 1.8 | 8 ± 1 |
| RAPTA-C | >200 | >200 | >200 |
a
Values are given as the mean ± SD (μM).